| 1 |
蒲丹, 唐朝枢. 关注生物活性小分子物质的研究[J]. 国外医学(生理、病理科学与临床分册), 2004, 24(5): 393-398.
|
| 2 |
何莲, 张爱华. 慢性肾脏疾病与透析患者ghrelin 研究现状[J].中国血液净化, 2005, 4(12): 665-668.
|
| 3 |
Yoshimoto A, Mori K, Sugawara A, et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure [J]. J Am Soc Nephrol, 2002, 13(11): 2748-2752.
|
| 4 |
Rodriguez Ayala E, Pecoits-Filho R, Heimburger O, et al.Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study [J]. Nephrol Dial Transplant, 2004,19(2): 421-426.
|
| 5 |
何莲, 张爱华, 阿拉塔,等. 腹膜透析和血液透析患者血浆Ghrelin 水平的研究[J]. 中国现代医学杂志,2007, 17(10):1153-1156.
|
| 6 |
Yang C, Wang Y, Liu H, et al. Ghrelin protects H9c2 cardiomyocytes from angiotensin Ⅱ-induced apoptosis through the endoplasmic reticulum stress pathway[J]. J Cardiovasc Pharmacol,2012, 59(5):465-471.
|
| 7 |
Ledderose C, Kreth S, Beiras-Fernandez A. Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function [J]. Recent Pat Endocr Metab Immune Drug Discov, 2011,5(1):1-6.
|
| 8 |
Sun G X, Ding R, Li M, et al. Ghrelin attenuates renal fibrosis and inflammation of obstructive nephropathy[J]. J Urol, 2014, Epub ahead of print.
|
| 9 |
Cheung WW, Mak RH. Ghrelin and its analogues as therapeutic agents for anorexia and cachexia in end-stage renal disease[J].Kidney Int, 2009,76(2): 135-137.
|
| 10 |
Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J]. Nature, 1999,401(6750): 282-286.
|
| 11 |
Douglas SA, Ohlstein EH. Human urotensin-Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease[J]. Trends Cardiovasc Med, 2000, 10(6): 229-237.
|
| 12 |
Bottrill FE, Douglas SA, Hiley CR, et al. Human urotensin-Ⅱ is an endothelium-dependent vasodilator in rat small arteries[J]. Br J Pharmacol,2000,130(8): 1865-1870.
|
| 13 |
Bai Q, Zhang J, Zhang AH, et al. Roles of human urotensin Ⅱ in volume resistance hypertension in peritoneal dialysis patients[J].Ren Fail, 2012,34(6): 713-717.
|
| 14 |
Zoccali C, Mallamaci F, Tripepi G, et al. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease[J]. Kidney Int,2006,69(7): 1253-1258.
|
| 15 |
Zoccali C, Mallamaci F, Benedetto FA, et al. Urotensin Ⅱ and cardiomyopathy in end-stage renal disease[J]. Hypertension,2008,51(2): 326-333.
|
| 16 |
Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin Ⅱ and urotensin Ⅱ receptor in human diabetic nephropathy[J]. Am J Kidney Dis,2004,44(5): 826-831.
|
| 17 |
白琼,阿拉塔,张爱华,等. 糖尿病患者尾加压素Ⅱ与肾小管损伤标志物的相关性研究. 中华临床医师杂志(电子版), 2013,7(6):2323-2326.
|
| 18 |
Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor[J]. J Neurochem,2000,74(1): 34-41.
|
| 19 |
Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy[J]. Am J Physiol Renal Physiol,2013,304(6): F788-F800.
|
| 20 |
Zhang BH, Wang W, Wang H, et al. Promoting effects of the adipokine, apelin, on diabetic nephropathy[J]. PLoS One,2013,8(4): e60457.
|
| 21 |
Wang LY, Diao ZL, Zhang DL, et al. The regulatory peptide apelin: a novel inhibitor of renal interstitial fibrosis[J]. Amino Acids,2014, 46(12): 2693-2704.
|
| 22 |
Seifirad S, Masoudkabir F. Apelin could reduce risk of contrastinduced nephropathy in patients with congestive heart failure[J].Med Hypotheses, 2013,81(5): 898-900.
|
| 23 |
Malyszko J,Malyszko JS,Pawlak K, et al. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure [J]. Adv Med Sci, 2008, 53(1): 32-36.
|
| 24 |
Nageav I, Bokarewa M, Tarkowski A, et al. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes[J]. PloS One, 2006, 1: e31.
|
| 25 |
Filkova M,Haluzik M,Gay S, et al. The role of resistin as a regulator of inflammation:Implications for various human pathologies[J]. Clin Immunol,2009,133(2): 157-170.
|
| 26 |
Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes[J]. Nature,2001,409(6818): 307-312.
|
| 27 |
Spoto B, Mattace-Raso F, Sijbrands E, et al. Resistin and allcause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients[J]. Nephrol Dial Transplant,2013,28(Suppl 4): 181-187.
|
| 28 |
Kaynar K, Kural BV, Ulusoy S, et al. Is there any interaction of resistin and adiponectin levels with protein-energy wasting among patients with chronic kidney disease[J]. Hemodial Int,2014,18(1): 153-162.
|
| 29 |
Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alphadependent myokine that drives bron-fat-like development of white fat and thermogenesis[J]. Nature,2012,481(7382): 463-468.
|
| 30 |
Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function-newly discovered association[J]. Peptides,2014,60: 51-55.
|
| 31 |
Wen MS, Wang CY, Lin SL, et al. Decrease in irisin in patients with chronic kidney disease[J]. PLoS One,2013,8(5): e64025.
|
| 32 |
Ebert T, Focke D, Petroff D, et al. Serum levels of the myokine irisin in relation to metabolic and renal function [J]. Eur J Endocrinol, 2014,170(4): 501-506.
|